Selsby JT. Rescue of dystrophic skeletal muscle by PGC-1␣ involves restored expression of dystrophin-associated protein complex components and satellite cell signaling. Duchenne muscular dystrophy is typically diagnosed in the preschool years because of locomotor defects, indicative of muscle damage. Thus, effective therapies must be able to rescue muscle from further decline. We have established that peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Pgc-1␣) gene transfer will prevent many aspects of dystrophic pathology, likely through upregulation of utrophin and increased oxidative capacity; however, the extent to which it will rescue muscle with disease manifestations has not been determined. Our hypothesis is that gene transfer of Pgc-1␣ into declining muscle will reduce muscle injury compared with control muscle. To test our hypothesis, adeno-associated virus 6 (AAV6) driving expression of Pgc-1␣ was injected into single hind limbs of 3-wk-old mdx mice, while the contralateral limb was given a sham injection. At 6 wk of age, treated solei had 37% less muscle injury compared with sham-treated muscles (P Ͻ 0.05). Resistance to contraction-induced injury was improved 10% (P Ͻ 0.05), likely driven by the five-fold (P Ͻ 0.05) increase in utrophin protein expression and increase in dystrophin-associated complex members. Treated muscles were more resistant to fatigue, which was likely caused by the corresponding increase in oxidative markers. Pgc-1␣ overexpressing limbs also exhibited increased expression of genes related to muscle repair and autophagy. These data indicate that the Pgc-1␣ pathway remains a good therapeutic target, as it reduced muscle injury and improved function using a rescue paradigm. Further, these data also indicate that the beneficial effects of Pgc-1␣ gene transfer are more complex than increased utrophin expression and oxidative gene expression.
Duchenne muscular dystrophy; utrophin; gene expression; oxidative; mdx CAUSED BY A MUTATION IN THE dystrophin gene, Duchenne muscular dystrophy (DMD) is the most common fatal X-linked disease. In healthy muscle, the dystrophin protein serves as a functional link between the actin cytoskeleton and the extracellular matrix (ECM) through the dystrophin-associated protein complex (DAPC) (8, 11, 49) . Production of an aberrant protein product results in a failure to adequately transmit forces to the ECM and results in damage to the sarcolemma, particularly during lengthening contractions, as well as a number of secondary effects. In addition to a failure to maintain calcium homeostasis, metabolic dysregulation is also associated with the disease (17, 32) . The culmination of these cellular events is impaired muscle function (39, 54, 55) , as contractile tissue is progressively replaced by adipose and fibrotic tissue (14) . DMD is typically diagnosed in preschool-aged boys, after the child shows impaired motor function. Patients are often wheelchair bound by age 12 and succumb to the disease due to respiratory complications or cardiomyopathy in the early 20s (15) .
DMD is modeled by the mdx mouse, which has a nonsense mutation in exon 23 (7, 56) . While the mdx mouse is dystrophin-deficient, it generally suffers a far milder phenotype than typical DMD patients. For example, there is generally no fatty infiltration into muscle, the lifespan is only moderately reduced (ϳ20%), and mobility is generally not affected (9) . The mdx mouse, however, does accurately recapitulate many aspects of the disease for a brief time in the hind limb muscles, while the diaphragm suffers a steady disease progression like that observed in human patients (13, 57) . Among the proposed explanations for the mild phenotype of mdx mice compared with DMD patients is that mdx mice have higher utrophin expression (26) . Utrophin is an autosomal dystrophin-related protein that is expressed at the neuromuscular junction (NMJ) in healthy muscle cells (20, 25) . Because utrophin has a similar structure to dystrophin (NH 2 and COOH termini, spectrin-like repeats, and hinge regions), it has been suggested that utrophin can serve as a functional substitute for dystrophin in dystrophic skeletal muscle (44, 61) . Indeed, dystrophin-deficient mice transgenically overexpressing utrophin and utrophin gene transfer in animal models have shown convincingly that increased utrophin expression will prevent and delay disease onset and rescue already declining muscle (23, 46, 60, 63) from some, but not all dystrophic pathologies (29) . Currently, however, a practical means of increasing utrophin expression is lacking for human patients.
Activation of the transcriptional coregulator, peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1␣), promotes the expression of utrophin at the NMJ, as well as more widely throughout the sarcolemma (2, 19) . Importantly, PGC-1␣ also regulates mitochondria biogenesis and promotes the expression of oxidative genes, which may help to offset metabolic dysregulation observed in dystrophic skeletal muscle (17, 27, 32, 65) . Moreover, PGC-1␣ has also been shown to lead to the expression of antioxidants, which may help to reduce free radical injury and maintain muscle function (21, 55, 64) . Indeed, dystrophin-deficient mice transgenic for increased Pgc-1␣ and gene delivery of Pgc-1␣ into neonatal mdx skeletal muscle have reduced muscle injury and improved muscle function compared with untreated muscle (22, 52) .
These early successes are promising and indicate that Pgc-1␣ overexpression will prevent disease onset. However, as most patients are diagnosed precisely because they have functional impairments, it indicates that they already have advanced disease-related injury sufficient to impact locomotion. Hence, it is important that interventions not only prevent the disease from developing but also prevent continued decline, and potentially even restore muscle function if initiated following the onset of muscle injury. In a recent investigation, Pgc-1␣ gene transfer was performed in 6-wk-old muscle in mdx mice (18) . Although ultimately effective in improving a number of pathological outcomes, 6-wk-old muscle is well into the regenerative phase of the early necrotic bout; hence, the extent to which PGC-1␣ alters typical pathology in actively declining muscle remains unknown. The aim of this study is to determine the extent to which Pgc-1␣ gene transfer rescues dystrophic muscle from typical disease-related decline during the initial necrotic bout. This purpose represents an important next step in a line of inquiry advancing PGC-1␣ pathway activation toward therapeutic application for DMD patients. Our hypothesis is that dystrophic skeletal muscles overexpressing PGC-1␣ will have less muscle injury and improved function compared with untreated muscles, indicating successful rescue of disease progression.
METHODS
Animal treatments. All animal procedures were approved by the Institutional Animal Care and Use Committee at Iowa State University and were done in accordance with the guiding principles established by the American Physiological Society. To determine the extent to which Pgc-1␣ gene transfer can rescue dystrophic muscle from disease-related decline, 3-wk-old dystrophin-deficient (mdx) mice were obtained from our colony. We have found that mdx mice from our colony begin to exhibit early signs of muscle injury at approximately this time. Mice were given a 50-l injection in a single triceps surae containing 1 ϫ 10 11 genome copies of AAV serotype six driving expression of Pgc-1␣ under the control of a modified chicken ␤-actin promoter (52) . We have previously used a similar technique to achieve infection of the muscles of a single limb, while the contralateral limb remained uninfected (52, 55) . The contralateral limb was injected with empty vector. At 6 wk of age, animals were brought to a surgical level of anesthesia with tribromoethanol, the soleus muscles were removed, and the mouse was killed by cervical dislocation. Soleus muscle pairs were randomly assigned to either biochemistry and were snap frozen in liquid nitrogen, or histology, and coated in freezing media and frozen in melting isopentane. In addition, a subset of animals were treated and designated for muscle function measures.
Histology. Ten-micrometer frozen sections were cut from soleus muscles and placed on slides. Hematoxylin-and-eosin staining was performed, according to standard techniques. Each soleus muscle was visualized using a Leica microscope at ϫ100, and multiple pictures were taken, so that the entire soleus was captured, generally using three to five images. Complete soleus muscles were digitally reconstructed using Photoshop, so that the entire muscle cross section was in a single picture file and could be readily analyzed. The reconstructed image was imported into OpenLab, so that areas of immune cell infiltration, hypercontracted cells, and hematoxylin-and-eosin (H&E)-negative cells could be quantified. These areas are expressed as a percentage of the total muscle cross-sectional area. H&E sections were further used to determine central nucleation. Briefly, the total number of muscle fibers and the total number of muscle fibers with centralized nuclei were counted in the reconstructed image using ImageJ. The total number of fibers with a centralized nucleus was made relative to the total number of fibers in the cross section, and the resulting percentage was reported. Counts were made by a blinded technician.
To identify utrophin protein localization and measure expression, slides were probed with antibody for utrophin (Vector VP-U579) directly labeled with Zeon Alexa Fluor 568 (Invitrogen Z25006). Slides were washed in PBS for 10 min and blocked for 15 min with 5% BSA. They were then exposed to labeled primary antibody (1:10) in 1% BSA and incubated for 60 min at room temperature in the dark. Slides were washed three times for 10 min in PBS. Coverslips were mounted using Vectashield with DAPI.
Utrophin expression and localization were visualized in two or three random sections/muscle at ϫ400. Importantly, all slides were prepared at the same time, and all images were taken using identical exposure conditions on the same microscope in random order. To quantify utrophin expression, images were imported into OpenLab, and the density slice function was used to transform the image into a binary image. In this fashion, pixels are identified as either above or below threshold intensity. Threshold was determined by measuring pixel intensity of intracellular and extracellular areas, where there should be no utrophin expression, as well as utrophin expression at several locations on the sarcolemma in several random sections. Importantly, all images were processed under identical conditions. For sections from control soleus muscles, the replicate with the greatest utrophin expression was used for analysis. Conversely, for the Pgc-1␣-treated limbs, the corresponding replicate with the lowest utrophin expression was used for analysis. The total area of utrophin expression that exceeded threshold was quantified and is expressed relative to control. As we compared the greatest utrophin expression from control soleus muscles to the lowest utrophin expression from corresponding treated muscles, our measurement of relative utrophin expression is likely conservative.
To determine fiber size distribution, slides were washed and blocked as described above. Overnight, sections were exposed to a primary antibody for laminin (NeoMarkers, RB-082-A) at a dilution of 1:100. Slides were then washed, and secondary antibody applied for 1 h at room temperature. Secondary antibody (goat anti-rabbitrhodamine conjugated; Millipore, 12-510) was used at a dilution of 1:100. Two random and nonoverlapping images were taken of each section at ϫ200. Using Image Pro, we measured minimum Feret diameter in each complete cell in these images, and resultant data were pooled for each muscle, resulting in the inclusion of 100 -180 fibers/muscle. Average fiber diameter was calculated as was the coefficient of variance (6) .
Muscle function. Muscle function (tetanic force, a series of eccentric contractions, and fatigue) was measured in the soleus at the Physiological Assessment Core of the Wellstone Muscular Dystrophy Cooperative Center at the University of Pennsylvania, according to standard techniques (3, 4, 36, 39, (52) (53) (54) (55) . Solei from different animals were used to measure eccentric injury and fatigue resistance, so that one measure would not interfere with the other. Force produced during these measures is normalized to the force produced during the initial contraction. Importantly, technicians performing these measures were blinded to the treatments.
Biochemistry. RNA was isolated from soleus muscles using TRIzol following the manufacturer's recommended instructions. Purified RNA was further processed using Qiagen RNeasy spin columns. Using the RT 2 first-strand kit (SABiosciences), we synthesized c-DNA from 1 g of purified RNA, following manufacturer's instructions. Subsequently, we performed quantitative PCR (qPCR) to determine Pgc-1␣ expression in treated and control limbs using the 18S ribosomal subunit as a loading control. We also measured expression of the autophagy markers Lc3 (Map1lc3a), Atg 12, Bnip 3, and Gabarap 1 in a similar manner. Additionally, cDNA was loaded into SABioscience mouse skeletal muscle: myogenesis and myopathy array (PAMM-099A), and qPCR reactions were run according to the manufacturer's recommendations. The array is a 96-well PCR plate seeded with mouse-specific primer pairs for 84 genes with known function in skeletal muscle myogensis and myopathy. These primer pairs have been extensively tested for target specificity, according to the manufacturer. Expression of all significantly different genes was increased; however, genes on the array were chosen because of their known involvement in pathological processes. In addition, the array includes controls for genomic contamination, successful reverse transcription, and a control to verify successful quantitative PCR, as well as suggested loading controls. Importantly, expression (CT value) of these loading controls, Gapdh and ␤-actin, was altered by our intervention. To determine an appropriate loading control, we compared CT values of all of the genes on the plates and chose titin and Slc2a4 because they had a combination of the highest P value and smallest fold change. To provide the most robust loading control, we normalized to the mean expression of these genes. Normalization to the 18S subunit was not possible because primers to the 18S subunit were not part of the array. Delta (⌬) CT values were calculated by subtracting the CT value from the experimental gene from the CT value of the control. These values were used for statistical comparisons. ⌬⌬CT was calculated by subtraction of the ⌬CT of a treated soleus muscle from the ⌬CT of the corresponding control soleus muscle. Data are presented as a fold change as calculated by ⌬⌬CT. Data points more than 2 SDs from the mean were excluded regardless of direction (above or below mean) or group resulting in the exclusion of 17/534 data points.
Statistics. Differences in muscle fatigue were evaluated with PROC MIXED in SAS. Remaining data were compared using paired t-tests.
Significance was set at P Ͻ 0.05. All data are expressed as means Ϯ SE unless otherwise noted.
RESULTS
To increase expression of Pgc-1␣, a virus driving Pgc-1␣ expression was injected into a single hind limb of 3-wk-old mdx mice, while the contralateral limb was injected with a null virus containing empty capsid. The 3-wk-old time point was chosen because soleus muscles from mdx mice in our colony show early signs of disease-related muscle injury, including immune cell infiltration and degeneration ( Fig. 1 ). Similar findings of early necrotic changes in limb muscles at this time point have been reported by others (7, 33, 45, 47) . Three weeks following viral injection, our gene delivery technique successfully increased expression of Pgc-1␣ in soleus muscles from treated limbs compared with soleus muscles from null limbs by ϳ11-fold ( Fig. 2 ; P Ͻ 0.05). Soleus muscle mass was similar between groups (mdx-Null: 6.2 Ϯ 0.2 mg; mdx-PGC-1␣: 6.1 Ϯ 0.2 mg; n ϭ 29); however, Pgc-1␣ gene transfer caused a reduction in gastrocnemius mass compared with null virustreated limbs (mdx-Null: 102.7 Ϯ 3.6 mg; mdx-PGC-1␣: 97.0 Ϯ 3.4 mg; P Ͻ 0.05; n ϭ 29). The large sample number reported for this measure is a combination of muscles used for histological, biochemical, and functional analyses.
Visual inspection of H&E-stained muscle cross sections revealed disease-related injury to both null-treated and Pgc-1␣-treated limbs, including foci of necrosis with apparent immune cell infiltration, hypercontracted cells, and H&Enegative staining fibers ( Fig. 3) . To determine the extent to which PGC-1␣ altered muscle condition, these areas were quantified. We found that areas of immune cell infiltration were reduced by 31% (P Ͻ 0.05), areas of hypercontracted cells by 65% (P Ͻ 0.05), and areas of H&E-negative cells by 43% (P Ͻ 0.05) in Pgc-1␣-overexpressing soleus muscles compared with null-virus-treated soleus muscles. In aggregate, this reduced the total area of damaged muscle by 37% (P Ͻ 0.05). The percentage of cells with centralized nuclei was similar between groups. Fiber area distribution was also similar between groups ( Fig. 4) , as was the mean minimum Feret diameter and coefficient of variation.
As the total damaged area was decreased in limbs overexpressing Pgc-1␣, we determined the extent to which Pgc-1␣ gene transfer would rescue muscle function in already declining muscle. Cross-sectional area, tetanic force, and specific tension were similar between groups ( Table 1) . As there is a rationale to suspect that PGC-1␣ can lead to utrophin expression and resultant resistance to contraction-induced injury, we measured force production in five eccentric contractions. Solei overexpressing Pgc-1␣ were able to produce ϳ10% more (P Ͻ 0.05) force than control solei during each contraction (Fig. 5) . To determine the extent to which Pgc-1␣ overexpression rescued mdx muscle from fatigue, muscles underwent an endurance challenge. Pgc-1␣ overexpressing solei maintained significantly higher force throughout the protocol (P Ͻ 0.05) ( Fig. 6 ). To better understand the mechanism underlying histological and functional rescue of dystrophic soleus muscles, we measured content and localization of utrophin protein using immunohistochemistry. Pgc-1␣ gene transfer resulted in a nearly five-fold (P Ͻ 0.05) increase in utrophin expression compared with null-treated soleus muscles (Fig. 7) . Importantly, this increase in utrophin was not localized to the neuromuscular junction, as utrophin was found throughout the sarcolemma.
Because PGC-1␣ is a transcriptional coactivator, it has the potential to alter expression of numerous genes; hence, we performed a PCR array. A PCR array is a 96-well plate preloaded with primers, in this case, for 84 genes involved in myogenesis and myopathy. This array (PAMM-099A, SABiosciences) was selected specifically because it contains primers for genes related to the dystrophin-glycoprotein complex, energy metabolism, and myogenesis, among other processes. Although many of these processes are grounded with sound hypotheses (i.e., increased expression of genes related to the DAPC and oxidative metabolism), this approach allowed us to better understand the widespread cellular effects underlying PGC-1␣-mediated rescue. Genes whose products are directly or indirectly associated with dystrophin and the DAPC were increased ϳ50% (range 33-85%) in soleus muscles overexpressing Pgc-1␣ compared with control muscles (Fig. 8 ). Expression of several sarcomeric genes was increased, although expression varied widely from 16%, twofold over control soleus muscles (Fig. 8) . Expression of metabolic genes was increased 18 -85% in soleus muscles from treated limbs compared with soleus muscles from control limbs ( Fig. 9) , although some metabolic genes failed to reach significance (see Supplemental Table S1 ). Genes related to satellite cell function were increased 31% to nearly twofold in soleus muscles overexpressing Pgc-1␣ compared with control soleus muscle (Fig. 10 ). There was a modest increase in genes associated with calcium-mediated protein degradation, as well as the atrogenes Fbxo 32 (Atrogin-1, MAFbx) and Trim 63 (MuRF 1) that was countered by an increase in genes associated with protein synthesis in treated limbs compared with control limbs (Fig. 11) . Surprisingly, inflammatory signaling was generally increased in treated limbs compared with control limbs. Tnf expression was increased 34-fold in treated limbs compared with control limbs and Il-6 and Il-1␤ were increased by four-and eight-fold, respectively (Fig. 12 ). Also, proapoptotic caspase 3 was increased by an approximate 2.6-fold; however, it was well matched with a similar increase in the antiapoptotic Bcl2 and ␣B crystalin (Fig. 12) . Given recent findings using a similar, but distinct, approach (43), we also measured expression of genes related to autophagy. Pgc-1␣ gene transfer caused a 50% and 86% increase in Lc3 (P Ͻ 0.05) and Atg12 (P Ͻ 0.05), respectively; however, the autophagy genes Bnip3 and Gabarap 1 were similar between Values are expressed as means Ϯ SE; n ϭ 11. Pgc-1␣ gene transfer did not improve cross-sectional area (CSA), tetanic force, or specific tension in solei overexpressing Pgc-1␣ compared to the contralateral control. treated and control soleus muscles (Fig. 13 ). Expression of genes that were similar between groups can be found in Supplemental Table S1 .
DISCUSSION
Duchenne muscular dystrophy is caused by a mutation in the dystrophin gene, giving rise to a nonfunctional protein product. Novel therapies approved for human use have been slow in coming; however, numerous experimental approaches are present in the literature (1, 5, 38, 39, (53) (54) (55) . Among the most successful is replacing the missing dystrophin protein with utrophin, a dystrophin-related protein (23, 46, 60, 63) . Although several strategies for potential use in humans are advancing (24, 35, 62) , their approval is not imminent, and drugs may prove ultimately unsuccessful. It is, therefore, critical to continue searching for pathways that can be modulated for therapeutic benefit. One possible solution is to increase expression of the coactivator, PGC-1␣, as previous work indicates PGC-1␣ drives utrophin expression through an N-box domain in the utrophin promoter (2, 22, 37) . As well as increased utrophin expression, PGC-1␣ also drives expression of oxidative proteins and antioxidants (21, 28, 64) , which may be therapeutic to dystrophic muscle, as metabolic dysregulation has been repeatedly reported (17, 27, 32, 65) . Moreover, as PGC-1␣ is a transcriptional coactivator, there is a likelihood that it will drive expression of additional genes that provide further means of disease mitigation.
An important consideration during therapy development is that DMD patients are generally diagnosed during the preschool years, when they display locomotor deficits, indicating that their muscles have already been damaged by the disease. Hence, interventions must have the potential to rescue declining muscle from continued disease-related muscle injury. We (52) , and others (22) , have previously established that increased Pgc-1␣ expression prior to muscle injury reduced the severity of disease and preserved muscle function compared with control muscles. Recently, it was shown that Pgc-1␣ gene transfer enhanced recovery from the initial necrotic bout experienced in the mdx model (18) ; however, as the intervention began when muscles would be predicted to be well into the recovery phase, little is known about the capacity of PGC-1␣ to protect actively declining muscle. In this investigation, our purpose was to extend these observations and determine the extent to which increased Pgc-1␣ expression rescued already declining muscle from continued disease-related muscle injury.
Our injection technique increased Pgc-1␣ expression by ϳ11-fold compared with control limbs. Pgc-1␣ expression measured by PCR array was similar between groups. One resolution to this discrepancy is that the array targets primers to the 3= UTR of the transcriptional product, which is lacking in the viral construct. In contrast, our primers are targeted to the middle of the transcriptional product. That endogenous gene expression is similar between limbs indicates that our intervention does not alter expression of endogenous Pgc-1␣.
We found that gene transfer of Pgc-1␣ into already declining muscle rescued dystrophic muscle from typical disease progression and specifically reduced the areas of immune cell infiltration, hypercontracted cells, and H&E-negative staining fibers. Additionally, Pgc-1␣ overexpression led to resistance to fatigue and injury caused by eccentric contractions. Previously, we found that Pgc-1␣ gene transfer to neonates protected the extensor digitorum longus from eccentric injury, but not the soleus (52). This subtle difference could stem from a more substantial increase of utrophin protein in the current study. Further inconsistencies are found in considering several distinct, but related, interventions: transgenic upregulation of Pgc-1␣, AICAR (AMPK agonist), and GW501516 (PPAR␤/␦ agonist). Transgenic Pgc-1␣ overexpression (22) and GW501516 (35) decreased eccentric injury; however, AICAR (31) did not. The increased fatigue resistance found in this study fits well with similar findings after Pgc-1␣ gene transfer in neonates (52) . Seconds Percent Initial Force Fig. 6 . Fatigue resistance was improved by Pgc-1␣ gene transfer. Soleus muscles from 6-wk-old mdx mice were tested for force production during repeated contractions (1/s) 3 wk following Pgc-1␣ gene transfer. The force produced by treated soleus muscles was significantly higher than the force produced by the control soleus muscles throughout the experimental protocol. n ϭ 6. . Force following eccentric contractions. Force decline following eccentric contractions was reduced by Pgc-1␣ gene transfer. Soleus muscles from 6-wk-old mdx mice were exposed to five lengthening contractions 3 wk following Pgc-1␣ gene transfer. After all contractions, the force produced by treated soleus muscles was higher compared with control. *Significantly different from mdx-null; n ϭ 5.
Consistent with our hypothesis, utrophin gene and protein expression were increased in treated soleus muscles compared with control muscles. Importantly, utrophin protein was located throughout the sarcolemma rather than just focused at the neuromuscular junction. Further, expression of agrin was increased in treated soleus muscles compared with control soleus muscles. This potentially provides a secondary means of utrophin expression through an agrin/heregulin pathway (26, 35) . Associated with increased utrophin expression was increased expression of sarcoglycan and dystroglycan, genes whose protein products comprise important parts of the DAPC, suggesting that utrophin is functioning as a dystrophin substitute. Of interest, accumulation of dystroglyan, independent of other treatments, has also been shown to decrease disease severity in dystrophic skeletal muscle (34) . Improved resistance to damage caused by lengthening contractions indicates that the DAPC components are not only increased but also are functioning. Indeed, numerous other investigations (1, 41) have found that increased utrophin expression leads to increased expression and localization of DAPC components. Increased expression of DAPC components may be directly or indirectly caused by PGC-1␣ gene transfer, but regardless, likely contributes to restoration of sarcolemma stability. PGC-1␣ gene transfer was expected to lead to robust expression of genes associated with mitochondrial respiration; however, we found this response to be relatively modest. Expression of several oxidative signaling molecules was in-creased, as expression of three AMPK subunits was increased ϳ50% and Pparg expression was nearly doubled. Consistent with these observations was increased citrate synthase expression, which would allow increased TCA cycle activity. Conversely, Gapdh expression was increased, and expression of several oxidative genes was similar between groups (Supplemental Table S1 ). While the direction of the change in gene expression was generally similar to previous investigations (40, 59) , the smaller magnitude of change is likely caused by the shorter duration of this study. Alternatively, it is possible that a rescue paradigm only partially restores metabolic function. Importantly though, the modest increase in oxidative genes translated into increased fatigue resistance in the Pgc-1␣-expressing solei compared with control muscles.
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Contrary to our expectations, the percent of muscle fibers with centralized nuclei, a measure of muscle repair, was similar in treated and nontreated soleus muscles. We anticipated that as PGC-1␣ pathway activation has been shown to increase utrophin expression and reduce muscle injury, the need for repair would be decreased in Pgc-1␣-overexpressing limbs and be reflected in a lower degree of centralized nuclei. Despite the clear reduction in muscle damage, demonstrated both histologically and functionally, central nucleation was similar between treated and control limbs. Likewise, treatment with GW501516, a PPAR␤/␦ agonist, which, also led to clear histological and functional benefits, did not result in reduction of central nucleation (35) . As both interventions used rescue as a model, as suggested by Miura et al. (35) , the central nuclei in this investigation could have resulted from earlier damage and repair.
Considering that muscle injury would be predicted to be similar upon treatment, that damage was far less in the PGC-1␣ overexpressing muscles following treatment, and centralized nucleation was similar, an attractive alternative is a PGC-1␣-mediated repair process. Indeed, genes leading to increased satellite cell activation (Pax7), proliferation (Pax7, Ffg2, Bmp4), self-renewal (Myf5), and differentiation (Mef2c, Myf5 in the presence of MyoD) were increased in treated soleus muscles compared with control (16, 42, 48, 50, 66, 67) . Further, PGC-1␣ has been shown to interact with and activate Mef2c (30) . This notion of a PGC-1␣-mediated repair process is intriguing, as the proliferative capacity of satellite cells appears to be limited with advanced disease in human patients (58) . Hence, a mechanism leading to increased muscle repair is of potential therapeutic importance. The role of autophagy in dystrophic skeletal muscle is an emerging area of focus, as recent investigations have found that increased (12) , not decreased (10), autophagy was associated with decreased disease-related injury. That AICAR led to increased autophagy (43) raised the possibility that PGC-1␣ gene transfer might also perform a similar function. Indeed, expression of Lc3 and Atg12, two key markers associated with autophagy, was induced by PGC-1␣, implicating another mechanism by which PGC-1␣ is decreasing disease-related muscle decline.
While findings generally support a role for increased PGC-1␣ expression as a therapy for dystrophin deficiency, we also measured gene expression contrary to our expectations. For example, despite reduced immune cell infiltration, we found evidence of increased Tnf signaling leading to cytokine production and increased expression of caspase 3 (38) . Contrarily, we also found evidence of apoptosis resistance (Bcl2, ␣B crystalin) in soleus muscles overexpressing PGC-1␣ compared with contralateral limbs. Further, augmented expression of calpains and atrogenes would suggest increased protein turnover in the PGC-1␣-treated limbs compared with control limbs and may help to explain decreased muscle mass found in this investigation and others using a similar strategy (31, 52) . Conversely, in healthy muscle, transgenic overexpression of Pgc-1␣ led to a reduction in expression of atrogenes after denervation or starvation (51) . The roles of inflammatory signaling, apoptosis, and protein turnover are important considerations and will be addressed in future investigations.
In summary, in this investigation, we found that PGC-1␣ gene transfer rescued dystrophic muscle from disease-related decline, suggesting that this strategy could be successful following diagnosis in human patients. We found increased expression of utrophin and DAPC components, increased oxidative gene expression, and autophagy, likely contributing to decreased muscle injury. This was complemented by data pointing toward increased satellite cell activation, indicating an elevated capacity for muscle repair. Thus, PGC-1␣ leads to multiple mechanisms that synergistically act to decrease disease severity in dystrophin-deficient skeletal muscle. Enthusiasm is dampened, however, as we also measured increased expression of atrogenes, genes involved in apoptotic signaling, and inflammation. Nevertheless, the successful interruption of the disease process through reduced muscle injury and improved muscle function points toward the therapeutic potential of this pathway.
